📊 AXIM Key Takeaways
Investment Thesis
AXIM is in severe financial distress with negative stockholders' equity of -9.5M, liabilities exceeding assets by 9.6M, and a cash position of only 6K despite long-term debt of 6M. The company is burning cash at an accelerating rate (-514K operating cash flow) while generating minimal revenue (70.5K), rendering it technically insolvent and at critical risk of bankruptcy without immediate capital restructuring.
AXIM Strengths
- Exceptional gross margin of 97.5% indicates strong unit economics on limited revenue
- Recent revenue growth of 345.3% YoY shows early commercial traction despite minimal absolute scale
- Pharmaceutical sector positioning may provide future revenue opportunities if operations stabilize
AXIM Risks
- Negative stockholders' equity of -9.5M indicates technical insolvency and potential bankruptcy risk
- Liquidity crisis with current ratio 0.00x and cash balance of 6K insufficient to cover operations
- Severe cash burn of -514K operating cash flow with virtually no offsetting revenue generation
- Long-term debt of 6M creates refinancing risk given negative equity and operational losses
- Net losses of 2.6M on 70.5K revenue unsustainable; operating margins of -1378% indicate fundamental business model failure
- Zero insider activity in 90 days suggests potential loss of confidence from management
Key Metrics to Watch
- Stockholders equity trend and timeline to recapitalization or restructuring
- Monthly revenue run rate and path to breakeven on operating expenses
- Cash position and runway remaining given -514K monthly cash burn
- Debt refinancing ability and covenant compliance status
- Quarterly operating cash flow for sustainability assessment
AXIM Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AXIM Profitability Ratios
AXIM vs Healthcare Sector
How AXIM BIOTECHNOLOGIES, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AXIM Balance Sheet & Liquidity
AXIM 5-Year Financial Trend
5-Year Trend Summary: AXIM BIOTECHNOLOGIES, INC.'s revenue has declined by 20% over the 5-year period, indicating business contraction. The most recent EPS of $-0.04 indicates the company is currently unprofitable.
AXIM Growth Metrics (YoY)
AXIM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $9.9K | -$292.3K | $-0.01 |
| Q1 2024 | $7.4K | -$292.3K | $0.00 |
| Q3 2023 | $1.3K | $328.5K | $0.00 |
| Q2 2023 | $9.9K | -$1.2M | $-0.01 |
| Q1 2023 | N/A | -$2.1M | $-0.01 |
| Q2 2022 | N/A | -$864.5K | $-0.01 |
| Q1 2022 | N/A | -$864.5K | $-0.01 |
| Q3 2021 | N/A | -$79.4K | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AXIM Capital Allocation
AXIM SEC Filings
Access official SEC EDGAR filings for AXIM BIOTECHNOLOGIES, INC. (CIK: 0001514946)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AXIM
What is the AI rating for AXIM?
AXIM BIOTECHNOLOGIES, INC. (AXIM) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AXIM's key strengths?
Exceptional gross margin of 97.5% indicates strong unit economics on limited revenue. Recent revenue growth of 345.3% YoY shows early commercial traction despite minimal absolute scale.
What are the risks of investing in AXIM?
Negative stockholders' equity of -9.5M indicates technical insolvency and potential bankruptcy risk. Liquidity crisis with current ratio 0.00x and cash balance of 6K insufficient to cover operations.
What is AXIM's revenue and growth?
AXIM BIOTECHNOLOGIES, INC. reported revenue of $70.5K.
Does AXIM pay dividends?
AXIM BIOTECHNOLOGIES, INC. does not currently pay dividends.
Where can I find AXIM SEC filings?
Official SEC filings for AXIM BIOTECHNOLOGIES, INC. (CIK: 0001514946) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AXIM's EPS?
AXIM BIOTECHNOLOGIES, INC. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.